EU expands scope of Teva’s Trisenox
European regulators have expanded the scope of Teva Pharmaceutical’s Trisenox, approving its use to treat patients with newly diagnosed Acute Promyelocytic Leukaemia (APL), a rare and aggressive type of blood cancer that can kill within hours or days if left untreated.
Read More
